Congratulations to Yury Bochkov, PhD, Principal Investigator, for his $50,000, 1-year award from Arctic Therapeutics, LLC, for this grant entitled, “Testing RV-C inhibitors and receptor function of animal CDHR3 sequences in HeLa cells.” The main objective of this project is to test the effects of four new antiviral compounds developed by Arctic Therapeutics, LLC on rhinovirus C (RV-C) binding and/or replication in transduced HeLa-E8 cells. In addition, receptor function of CDHR3 protein, a transmembrane protein that serves as a cellular receptor for RV-C, from some animal species (e.g., mouse, marmoset, rhesus macaque) will be tested.